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Objective: We determined if the epidermal growth factor receptor ligand HB-EGF is produced in cartilage
and if it regulates chondrocyte anabolic or catabolic activity.
Methods: HB-EGF expression was measured by quantitative PCR using RNA isolated from mouse knee
joint tissues and from normal and osteoarthritis (OA) human chondrocytes. Immunohistochemistry was
performed on normal and OA human cartilage and meniscus sections. Cultured chondrocytes were
treated with ﬁbronectin fragments (FN-f) as a catabolic stimulus and osteogenic protein 1 (OP-1) as an
anabolic stimulus. Effects of HB-EGF on cell signaling were analyzed by immunoblotting of selected
signaling proteins. MMP-13 was measured in conditioned media, proteoglycan synthesis was measured
by sulfate incorporation, and matrix gene expression by quantitative PCR.
Results: HB-EGF expression was increased in 12-month old mice at 8 weeks after surgery to induce OA
and increased amounts of HB-EGF were noted in human articular cartilage from OA knees. FN-f stimu-
lated chondrocyte HB-EGF expression and HB-EGF stimulated chondrocyte MMP-13 production. How-
ever, HB-EGF was not required for FN-f stimulation of MMP-13 production. HB-EGF activated the ERK and
p38 MAP kinases and stimulated phosphorylation of Smad1 at an inhibitory serine site which was
associated with inhibition of OP-1 mediated proteoglycan synthesis and reduced aggrecan (ACAN) but
not COL2A1 expression.
Conclusion: HB-EGF is a new factor identiﬁed in OA cartilage that promotes chondrocyte catabolic ac-
tivity while inhibiting anabolic activity suggesting it could contribute to the catabolic-anabolic imbalance
seen in OA cartilage.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The progressive degradation and loss of articular cartilage dur-
ing the development of osteoarthritis (OA) is thought to be due to
an imbalance in chondrocyte anabolic and catabolic activity1. AnR.F. Loeser, Thurston Arthritis
d Immunology, University of
Chapel Hill, NC, 27599-7280,
Long), vulici@email.unc.edu
skaya), richard_loeser@med.
ternational. Published by Elsevier Limportant goal of OA research has been to identify the factors that
promote catabolic over anabolic activity with the hope that one or
more of these mediators might serve as a therapeutic target. A host
of soluble mediators capable of regulating chondrocyte activity
have been found to be produced locally by the articular chon-
drocytes and act in an autocrine and paracrine fashion. These
include various growth factors, cytokines, chemokines, Wnt family
members, and toll-like receptor agonists, to name just a few. It is
also well recognized that these and other factors produced by
neighboring joint tissues, including the synovium, subchondral
bone, and the menisci in the knee, can also regulate chondrocyte
activity to promote catabolic over anabolic activity2. Despite the
number of factors identiﬁed to date, it is not known whichtd. All rights reserved.
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diators not yet studied may also be involved.
In an attempt to discover novel biological mediators that could
contribute to OA, we recently performed a computational analysis
of gene expression microarray data generated using RNA isolated
from knee joint tissues during a time course experiment in mice3.
OA was induced using the destabilized medial meniscus (DMM)
model and RNA was isolated from knee joint tissues at baseline, 2,
4, 8, and 16 weeks after surgery. We focused on signaling and
metabolic pathways and found a subnetwork, signiﬁcantly regu-
lated during the development of OA, that included a potential
proteineprotein interaction link betweenmatrixmetalloproteinase
(MMP)-2 and the epidermal growth factor receptor (EGFR) via
heparin-binding epidermal growth factor-like growth factor (HB-
EGF).
There is very little data on HB-EGF in joint tissues with one
study showing a 2.76-fold difference in HBEGF gene expression in
damaged relative to intact cartilage obtained at the time of joint
replacement surgery for knee OA4. HB-EGF can serve as a ligand for
the EGFR and activation of the chondrocyte EGFR by transforming
growth-factora (TGFa) has been shown to stimulate MMP expres-
sion and cartilage degradation as well as inhibit Sox-9 expression
and anabolic activity5,6. We postulated that HB-EGF could be
another mediator that promotes catabolic over anabolic activity in
cartilage. Therefore, the objective of the present study was to
investigate HB-EGF expression and production in normal and OA
cartilage and determine its effects on chondrocyte catabolic and
anabolic activity.
Methods
Reagents
Phospho-ERK, phospho-p38, phospho-Smad1ser206, phospho-
Smad1ser463/465/Smad5ser463/465/Smad8ser465/467, total Smad1, total
p38, and total ERK antibodies were from Cell Signaling (Beverly,
MA). MMP-13 antibody was from Abcam (Cambridge, MA). HB-EGF
antibody, HB-EGF ELISA duoset, MMP-13 ELISA, EGF receptor in-
hibitor AG1478, ERK inhibitor U0126, and recombinant HB-EGF
were from R&D Systems (Minneapolis, MN). P38 inhibitor
SB203580 and MMP-2 antibody were from EMD Millipore (Bill-
erica, MA). Control siRNA and smartpool siRNA against HB-EGF
were from Dharmacon (Lafayette, CO). Amaxa nucleofection re-
agents for transfection were from Lonza (Walkersville, MD). Pre-
designed MMP-13, HB-EGF, COL2A1, ID1, SMAD6, TGFa, and a5
integrin (ITGA5) real-time PCR primers were from SuperArray
Biosciences (Frederick, MD). Primers for TBP, B2M, and ACAN were
from the Wake Forest School of Medicine DNA laboratory. Se-
quences for these are provided in Table S1. AMV Reverse Tran-
scriptase and RT2 SYBR® green ROX™ qPCR Mastermix were
purchased from Promega and Qiagen, respectively. Recombinant
ﬁbronectin fragment containing the RGD cell binding domain was
produced using an expression construct provided by Dr Harold
Erickson (Duke University, Durham, NC). Vectastain Elite ABC kit
and Nova Red substrate were from Vector Labs (Burlingame, CA).
PicoGreen DNA assay was from Invitrogen (Carlsbad, CA). Mayer's
Hematoxylin was from Sigma (St. Louis, MO).
Tissue acquisition and chondrocyte isolation
Normal human ankle articular cartilage was obtained from
deceased tissue donors with no known history of arthritis from the
Gift of Hope Organ and Tissue Donor Network (Itasca, IL) through
the Department of Biochemistry at Rush University Medical Center
(Chicago, IL). Tissue from a total of 35 individual donors with agesfrom 46 to 77 years (avg 64 years) was used for cell culture studies.
Chondrocytes were isolated with sequential pronase and collage-
nase digestion and plated at high density monolayer as previously
described7. All cells were used without passaging to ensure proper
phenotype was retained.
Immunohistochemistry
Cartilage and medial meniscal sections used for immunohisto-
chemistry were fromyoung normal (n¼ 4, ages 36e48), old normal
(n ¼ 4, ages 68e76) and OA (n ¼ 4, ages 64e90) donors and were a
kind gift of Dr Martin Lotz (Scripps Research Institute, La Jolla, CA).
Although the current study focused on HB-EGF in cartilage, we
examined HB-EGF levels in the meniscus as a comparison to
cartilage, in particular because the outer region of the meniscus
contains blood vessels which would be expected to contain HB-EGF
and could serve as a positive immunostaining control. The sections
embedded in parafﬁn were deparafﬁnized followed by staining
with Vectastain Elite Kit (Vector Labs) according to manufacturer's
instructions. Tissuewas incubated overnight at 4Cwith a 10 mg/mL
goat anti-HBEGF antibody. Tissue incubated with no primary anti-
body was used as a negative control. Staining was visualized with
ImmPACT Nova Red substrate (Vector Labs). Nuclei were visualized
by Mayer's Hematoxylin staining. Images were captured using the
indicated objectives.
Quantitative real-time PCR
The RNA used for measuring HB-EGF expression in the DMM
model of OA was from a previously published microarray study8.
RNA from sham control and DMM knees joints was subjected to
real-time PCR analysis using predesigned primers speciﬁc for
mouse HB-EGF. HB-EGF levels were normalized to the expression of
TATA box-binding protein measured in parallel samples. For studies
using isolated human chondrocytes, RNA was isolated from
conﬂuent monolayers using TRIzol and primers speciﬁc for human
HB-EGF were used. RNA isolation and real-time PCR were per-
formed as previously described9. RNA was also isolated directly
from frozen samples of articular cartilage obtained from normal
tissue donors (n¼ 7, mean age 53 years) and OA (n¼ 5, mean age 57
years) patients who had undergone knee arthroplasty. For this, the
tissue was ﬁrst ground to a powder using the BioPulverizer system
(BioSpec Products, Inc. #59012MS) which was pre-chilled in liquid
nitrogen. 50e100 mg of cartilage powder from each sample was
further homogenized in 2 ml of TRIzol using a 3 ml syringe with an
18G needle. RNA was isolated from the aqueous phase after Chlo-
roform separation. Following isopropanol precipitation and 70%
ethanol washes, the resulted RNA pellet was dissolved in 100 ml of
dH2O followed by a cleanup step using the RNeasy Mini Kit (Qia-
gen). RNA concentration was measured using the NanoDrop 2000
(Thermo Scientiﬁc) and quality was veriﬁed using the Agilent
Technologies 2200 TapeStation. 600 ng total RNA per sample was
then converted to cDNA using AMV Reverse Transcriptase (Prom-
ega). The resulted cDNA was diluted 4 times and analyzed by real-
time PCR using the Bio-Rad CFX96 Real-Time System and CFX
manager analysis software.
Immunoblotting
Conditioned media and cell lysates were collected and used for
immunoblotting as previously described7. Primary antibodies were
diluted to 1:1000 and immunoreactive bands were detected using
chemiluminescence. All immunoblotting experiments were
repeated at least 3 times with cells from different donors. For
analysis of HB-EGF levels in conditioned media in response to
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a control which in previous studies we had found did not change
with FN-f treatment10.
Chondrocyte transfection
Chondrocytes were transfected by the nucleofection method,
using a human chondrocyte nucleofection kit (Lonza) as
described previously11. Brieﬂy, 2 million isolated cells were
resuspended in transfection reagent and nucleofected with
1000 nm of siRNA for HB-EGF or control nontargeting siRNA.
After the recovery period of 48 h, cells were made serum-free
overnight before stimulation.
Proteoglycan synthesis assay
The [35S]sulfate incorporation assay was performed to measure
proteoglycan synthesis. Chondrocytes were cultured in serum-free
medium in monolayer for overnight stimulation using 100 ng/mL
OP-1 with or without 10 ng/mL HB-EGF. The next day the mediumFig. 1. HB-EGF is increased in a mouse model of OA and in human OA cartilage. (A) OA wa
(n ¼ 9 sham controls and n ¼ 9 DMM) and 12 month-old mice (n ¼ 9 sham controls and n ¼
pooled from three animals per group were used for real-time PCR normalized to TBP as a
condition. (B) Immunohistochemical staining for HB-EGF on human cartilage sections from a
70 year-old) and young normal donor meniscus (d, 48 year-old). Colorimetric detection w
donors for each group (young normal, old normal, and OA). (C) Real-time PCR analysis for HB
OA (n ¼ 5, avg. age 57.4 years) cartilage samples normalized to B2M expression as a controwas replaced with fresh serum-freemedium 1 h prior to incubation
with [35S]sulfate for another 4 h [35S]sulfate incorporation was
measured using the Alcian blue precipitation method and
normalized to DNA content9. DNA was quantitated by PicoGreen
double-stranded DNA assay according to the manufacturer's
protocol.
Statistical analysis
Each experiment was performed at least three times with cells
from independent tissue donors for normal tissue and independent
OA knee joint tissues for OA. The number of independent samples
used for each experiment is provided in the ﬁgure legends and the
total number of independent samples used for cell culture,
immunohistochemistry, and RNA isolation are provided in the
respective sections of the methods above. Statistical analysis was
performed using Statview software (SAS Institute) or with Prism 6
(GraphPad). Results were analyzed by analysis of variance (ANOVA)
and Fisher's PLSD (Statview) or Tukey's test (Prism) for post hoc
testing.s surgically-induced by destabilization of the medial meniscus (DMM) in 12 week-old
9 DMM). RNA was isolated from the knee joint tissue at 8 weeks after surgery. Samples
housekeeping gene. Results are the mean ± sem of three independent RNA pools per
young normal donor (a, 45 year-old), OA patient (b, 90 year-old), old normal donor (c,
as with NovaRed substrate. Results are representative of staining from four different
-EGF expression using RNA isolated directly from normal (n ¼ 7, avg age 53.1 years) and
l.
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HB-EGF is increased in mouse and human OA knee joints
A recent gene microarray study from our group revealed that
heparin-binding EGF-like growth factor (HB-EGF) was up-regulated
following DMM surgery in knee joint tissue from both 12 week-old
and 12 month-old mice8. In that study, the histological scores for
OA in the older group of mice were twice that of the young which
was accompanied by signiﬁcant differences in gene expression
related to both age and OA. To conﬁrm the HB-EGF results on the
gene array, we subjected samples from the same study to real-time
PCR analysis for HB-EGF expression. HB-EGF was increased at 8
weeks after DMM surgery in the 12 week-old animals (þ39%)
relative to 12 week-old sham controls, although the difference was
not signiﬁcant (P ¼ 0.11). However, HB-EGF expression was ~494%
greater in the 12 month-old DMM animals relative to age-matched
sham controls (P < 0.001; Fig. 1(A)).
We next determined if we could detect HB-EGF protein in adult
human cartilage. Sections of human tibial plateaus from both
normal donors and OA joints were subjected toFig. 2. HB-EGF expression is increased by ﬁbronectin fragment (FN-f) and is secreted
by cells after FN-f treatment. (A) Chondrocytes were stimulated with 1 mM FN-f for
30 min, 1 h, 3 h, and 6 h. RNA was collected and real-time PCR was performed for HB-
EGF expression. Results are the mean ± sem of three experiments using cells from
independent donors. *P < 0.0001 vs control; **P ¼ 0.006 vs control (B) Chondrocytes
were stimulated overnight with 1 mM FN-f or 100 ng/ml OP-1. Conditioned media was
collected and concentrated prior to SDS-PAGE and immunoblotting with anti-HBEGF
antibody. Blots were stripped and reprobed for MMP-2 as a loading control. Results
are representative of experiments with cells from three independent donors.immunohistochemical staining with anti-HB-EGF antibody. HB-
EGF immunostaining was increased in OA cartilage relative to
normal and was mainly localized to cells [Fig. 1(B)]. We did not see
any signiﬁcant differences when comparing normal cartilage sec-
tions from young and older adults. We also examined meniscal
tissue from the same joints and noted strong HB-EGF immuno-
staining in both cells, particularly in blood vessels (where HB-EGF
would be expected), and diffusely in the matrix [Fig. 1(B)]. There
was no apparent difference between menisci from normal and OA
joints (Supplemental Fig. 1(S)). HB-EGF expression in cartilage was
further investigated using RNA isolated directly from normal and
OA human cartilage that was matched for age (avg age 53.1 years
for normal and 57.4 years for OA). The levels of HB-EGF were on
average 2-fold higher in RNA from OA cartilage [Fig. 1(C)].Fig. 3. Role of HB-EGF in MMP-13 production. (A) Chondrocytes were stimulated
overnight with increasing doses of HB-EGF. Media was collected and immunoblotted
for MMP-13. Blots were stripped and reprobed for MMP-2 as a loading control. Results
are representative of experiments performed with cells from three independent do-
nors. (B) Chondrocytes were stimulated overnight with 1 mM ﬁbronectin fragment (FN-
f) with or without the addition of 10 ng/mL HB-EGF. Media was collected and
immunoblotted for MMP-13 followed by MMP-2. Results are representative of ex-
periments performed with cells from three independent donors. (C) Chondrocytes
were treated with FN-f or the combination of FN-f and HB-EGF as in (B) with or
without pretreated with 250 nM AG1478, an EGF receptor inhibitor. Media was
collected and analyzed for MMP-13 production by commercially available ELISA. Re-
sults are mean ± sem from four independent donors. *P ¼ 0.0005 vs control;
**P < 0.0001 vs control; ***P ¼ 0.0003 vs control.
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stimulation of normal human chondrocytes
Since HB-EGF was found at increased levels in OA tissue, we
examined if a catabolic stimulus would increase chondrocyte
expression of HB-EGF. We chose to use recombinant ﬁbronectin
fragments (FN-f) as a model for catabolic stimulation of chon-
drocytes. FN-f are found at increased levels in OA tissue12,13 and
stimulate chondrocyte and meniscal cell catabolic signaling that
results in increased production of cytokines, chemokines and
MMPs that are relevant to OA11,14,15. In time course experiments
from 30 min to 6 h, FN-f increased chondrocyte HB-EGF expression
that peaked at 3 h [Fig. 2(A)]. We also examined expression of TGFa
which, like HB-EGF, serves as a ligand for the EGF receptor. We did
not ﬁnd a signiﬁcant increase in TGFa in response to FN-f although
we did detect a signiﬁcant increase in expression of the a5 integrin
subunit which, with the b1 integrin subunit, forms the a5b1 FN
receptor (Supplemental Fig. 2(S)). HB-EGF was increased in condi-
tioned media from human chondrocytes cultured overnight in the
presence of FN-f but not in cells treated with the anabolic growth
factor OP-1 [Fig. 2(B)].
HB-EGF promotes MMP-13 production, but is not required for
ﬁbronectin fragment induced MMP-13 production
After showing that HB-EGF is increased in OA cartilage and that
its expression and release by chondrocytes is stimulated by FN-f,
we measured the effect of HB-EGF on production of MMP-13, a
collagen degrading enzyme that plays a key role in cartilage
destruction in OA16e18. We stimulated chondrocytes with
10e100 ng/ml HB-EGF and found that doses of 50 and 100 ng/mL
were able to stimulate chondrocyte MMP-13 production [Fig. 3(A)].
HB-EGF signals through the EGF receptor and in a recent study weFig. 4. Effects of HB-EGF on a5 integrin expression and ﬁbronectin fragment-induced MMP-
100 ng/mL HB-EGF. RNA was isolated and analyzed for expression of a5 integrin (ITGA5) by
control; **P ¼ 0.0134 vs control. (B) Chondrocytes were stimulated overnight with 1 mM FN-
isolated and analyzed for expression of MMP-13 and HB-EGF (C) by real-time PCR. Results a
control; ***P ¼ 0.001 vs control.found that EGF receptor ligands enhanced FN-f stimulation of
MMP-13 production19. We therefore tested the effect of low dose
HB-EGF co-stimulation on FN-f mediated MMP-13 production. At
10 ng/mL, HB-EGF increased FN-f mediated MMP-13 production
[Fig. 3(B)]. This effect was blocked when cells were pretreated with
the EGF receptor inhibitor AG1478 [Fig. 3(C)]. We had previously
shown19 that AG1478 did not block FN-f induction of MMP-13
indicating that HB-EGF but not FN-f signals through the EGFR to
stimulate MMP-13 production.
A recent report has indicated that HB-EGF can up-regulate a5b1
integrin expression in intestinal epithelial cells20 and this integrin
is required for matrix degrading effects of FN-f21. We treated
chondrocytes with HB-EGF for 0.5, 1, 3, and 6 h and found that a5
integrin expression was signiﬁcantly increased at 3 and 6 h
[Fig. 4(A)]. We next determined if HB-EGF was required for FN-f
mediated MMP-13 production. We transfected chondrocytes with
siRNA to silence HB-EGF expression and then stimulated with FN-f.
Silencing of HB-EGF had no effect on FN-f mediated MMP-13
expression [Fig. 4(B)] despite a signiﬁcant reduction in HB-EGF
expression [Fig. 4(C)]. Together, these results suggest that HB-EGF
can promote FN-f mediated MMP-13 production and a5b1
expression but HB-EGF is not required for FN-f stimulation of MMP-
13 expression.
HB-EGF inhibits anabolic signaling mediated by OP-1
We also tested for a potential anti-anabolic activity of HB-EGF.
Reports have indicated that EGF signaling can inhibit bone
morphogenetic protein (BMP) signaling through mitogen activated
protein (MAP) kinase-mediated phosphorylation of Smad1 at
inhibitory serine residues, including serine 206, present in the
Smad1 linker region22. We therefore sought to determine if HB-EGF
could lead to phosphorylation of this inhibitory region on Smad113 expression. (A) Chondrocytes were stimulated for 0 (control), 0.5, 1, 3, and 6 h with
real-time PCR. Results are mean ± sem from three independent donors. *P ¼ 0.002 vs
f with or without inhibition of HB-EGF expression using small interfering RNA. RNA was
re mean ± sem from four independent donors. *P ¼ 0.013 vs control; **P ¼ 0.0097 vs
Fig. 5. HB-EGF induces inhibitory Smad1 phosphorylation through MAP kinases. (A) Chondrocytes were stimulated for 30 min with control media, 10 ng/ml HB-EGF, 100 ng/ml OP-
1, or the same doses of HB-EGF þ OP-1. Cell lysates were immunoblotted with antibodies against Smad1 phosphorylated on Ser206 or Ser463/465 present in Smad1,5,8. Blots were
stripped and reprobed for total (T) Smad1 or b-actin. Densitometric results using cells from four independent donors are shown to the right of the blots (mean ± sem). (B)
Chondrocytes were stimulated for 30 minwith 10 ng/mL HB-EGF. Cell lysates were immunoblotted with antibodies against phosphorylated (P) and total (T) ERK and p38. Results are
representative of experiments with cells from four independent donors. (C) Chondrocytes were pretreated for 30 min with either 10 mM U0126 (ERK inhibitor), 10 mM SB203580
(p38 inhibitor), or the combination of the two prior to stimulation with 10 ng/mL HB-EGF for 30 min. Cell lysates were immunoblotted with antibodies against Smad1 phos-
phorylated on serine206 and total Smad1. Results are representative of three independent donors.
Fig. 6. HB-EGF inhibits OP-1 mediated proteoglycan synthesis. Chondrocytes were
stimulated overnight with 100 ng/mL OP-1 or the combination of OP-1 and 10 ng/mL
HB-EGF. Proteoglycan synthesis was measured using [35S]sulfate incorporation and
DNA was analyzed with a PicoGreen assay. Results were normalized to unstimulated
controls set as one and are mean ± sem of four independent donors.
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phosphorylation at the inhibitory serine 206 was seenwith HB-EGF
and HB-EGF plus OP-1 but not OP-1 alone [Fig. 5(A)]. HB-EGF did
not stimulate phosphorylation of the activating site, which is at
serine 463/465 present in Smads1 and 5, and 465/467 in Smad8,
and did not alter the ability of OP-1 to stimulate the active site
serines. Treatment of chondrocytes for 30 min with 10 ng/mL HB-
EGF stimulated phosphorylation of both the ERK and p38 MAP ki-
nases [Fig. 5(B)]. The inhibitory Smad1 serine 206 phosphorylation
noted with HB-EGF was modestly reduced with inhibition of ERK
but not p38, and was completely blocked when both p38 and ERK
were inhibited at the same time, suggesting that both MAP kinases
contributed to HB-EGF induced Smad1 serine 206 phosphorylation
[Fig. 5(C)].
Having shown that HB-EGF can phosphorylate inhibitory resi-
dues on Smad1, we determined the effect of HB-EGF treatment on
BMP mediated anabolic effects in chondrocytes. We stimulated
chondrocytes with 100 ng/mL OP-1 (BMP-7) overnight, either with
or without co-treatment with 10 ng/mL HB-EGF, and measured the
synthesis of proteoglycans using sulfate incorporation. OP-1 stim-
ulated proteoglycan synthesis was inhibited in the presence of HB-
EGF (Fig. 6). This suggests that HB-EGF can antagonize chondrocyte
anabolic signaling mediated by OP-1. Proteoglycan synthesis in
cultures treated with HB-EGF alone did not differ from untreated
Fig. 7. HB-EGF inhibits OP-1 stimulation of aggrecan but not COL2A1, ID1, or SMAD6 expression. Chondrocytes were treated overnight with control media, 10 ng/ml HB-EGF, 100 ng/
ml OP-1, or the same amounts of HB-EGF þ OP-1. RNA was isolated and used for quantitative PCR with primers for aggrecan (A), COL2A1 (B), ID1 (C), and SMAD6 (D). Results shown
are the mean ± sem of samples from four independent donors.
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synthesis (data not shown).
Finally, we examined the effect of HB-EGF on OP-1 mediated
gene expression. HB-EGF inhibited OP-1 stimulation of aggrecan
expression but did not alter expression of COL2A1 [Fig. 7(A) and
(B)]. We also examined expression of ID1 and SMAD6 which are
two BMP target genes but did not detect an effect of HB-EGF on the
ability of OP-1 to upregulate these genes [Fig. 7(C) and (D)].
Therefore, the inhibitory effects of HB-EGF, at the 10 ng/ml dose
tested, appeared to be limited to OP-1 stimulation of aggrecan
expression and proteoglycan synthesis suggesting a different
mechanism of regulation from COL2A1, ID1, and SMAD6 or that
higher amounts of HB-EGF would be needed to inhibit these genes.
Discussion
Using results from a prior gene array study to identify potential
contributors to the development of OA, we found that the EGF re-
ceptor ligand HB-EGF is present in OA cartilage and is expressed by
OA chondrocytes. Production of HB-EGF by normal chondrocytes
was stimulated by FN-f, a catabolic stimulus, and promoted FN-f
stimulation of MMP-13 production. HB-EGF was also found to
have anti-anabolic properties through stimulation of Smad1
phosphorylation at an inhibitory site and this was associated with
inhibition of OP-1 mediated aggrecan expression and proteoglycan
synthesis. Thus, increased HB-EGF in OA could contribute to the
well characterized imbalance in catabolic and anabolic activity that
promotes joint tissue destruction.
Like the other EGFR ligands, HB-EGF is synthesized in a pro-form
as a transmembrane protein that is cleaved by proteolytic enzymes
including ADAM-10 and -12 and MMP-2, -3, and -923. Increased
MMP production by OA chondrocytes could promote HB-EGF
release where it would act in an autocrine and paracrine fashion
to stimulate EGFR signaling. We found that treatment of chon-
drocytes with FN-f increased HB-EGF expression and resulted inincreased release of HB-EGF into the conditioned media. We have
previously shown that FN-f stimulates production of multiple
MMPs by chondrocytes including MMP-310 and more recently
found that they also stimulate meniscal cells to produce MMPs that
would be capable of cleaving and releasing HB-EGF15.
AlthoughHB-EGFwas not required for FN-f stimulation ofMMP-
13 expression, addition of HB-EGF with FN-f resulted in greater
MMP-13 production than FN-f alone. Inhibition of the EGF receptor
blocked this effect, consistent with a mechanism involving HB-EGF
stimulation of EGF receptor signaling. Because FN-f requires acti-
vation of the ERK and p38 MAP kinases to stimulate MMP-13
expression7,13, it is possible that HB-EGF, which also activates
these pathways through the EGFR, promotes a higher level of
signaling resulting in increased MMP-13. The ability of HB-EGF to
increase a5 integrin expression could also promote the response to
FN-f by increasing the number of receptors for FN-f. A previous
study in Vero, A431, and MG63 cells found that HB-EGF could form
a complex with the diphtheria toxin receptor-associated protein
(DRAP27)/CD9 and the a3b1 integrin but not with a5b124 making it
unlikely that HB-EGF is directly interacting with the chondrocyte
a5b1 integrin.
A role for EGFR-mediated signaling in OA has been previously
proposed and the ﬁndings to date support a role for EGFR ligands in
promoting cartilage catabolic gene expression while inhibiting
chondrocyte anabolic activity. Treatment of rabbit articular chon-
drocytes with EGF was found to increase COX-2 expression and
PGE2 levels and to inhibit collagen expression and proteoglycan
synthesis25. The EGFR ligand TGFa was shown to be present in OA
cartilage and to promote cartilage degradation through increased
MMP expression as well as to inhibit expression of Sox-9 and ma-
trix genes5,6,26. We found that HB-EGF at 10 ng/ml inhibited
aggrecan expression but not COL2A1. This ﬁnding is similar to a
previous study from our lab9 where we found that activation of the
ERK MAP kinase with constitutively active MEK inhibited aggrecan
but not COL2A1 expression. Because HB-EGF activates ERK it may
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aggrecan and collagen expression. Similar to our ﬁndings with HB-
EGF, both EGF and TGFa signaling in chondrocytes included acti-
vation of the MAP kinases ERK as well as p386,25. It is possible that
the level of activation of ERK and p38 differs among the EGFR li-
gands resulting in differential effects on gene expression or that
there is a dose effect, such that higher doses of HB-EGF would be
needed to inhibit COL2A1, ID1, and SMAD6 expression thanwhat are
needed to inhibit aggrecan expression.
Further evidence that EGFR signaling can promote OA is pro-
vided by studies of mitogen-inducible gene 6 (Mig-6)mice. Mig-6 is
a negative regulator of EGFR signaling and deletion ofMig-6 in mice
has been used to study the effects of excessive EGFR activity on
joint tissues. Mice with systemic deletion of Mig-6 were found to
have ﬁbrocartilagenous hyperplasia, excessive osteophyte forma-
tion and early onset OA that was evident by 3 months of age27.
Cartilage speciﬁc deletion of Mig-6 in ﬂoxed mice using Col2a1Cre
also resulted in early-onset OA in knee joints after an initial
thickening of the cartilage due to excessive chondrocyte prolifera-
tion28. Of potential relevance to our ﬁnding of HB-EGF in the
meniscus, Mig-6 was also found to be expressed in the meniscus
and deletion in the meniscus appeared to contribute to the devel-
opment of knee OA28.
HB-EGF is expressed in vascular tissues andmicewith a deletion
of HB-EGF were noted to die soon after birth due to defects in heart
and lung development29. Of interest to our results showing HB-EGF
inhibition of chondrocyte OP-1 signaling, lack of HB-EGF in mice
resulted in excessive Smad1/5/8 activation in heart valves, sug-
gesting that HB-EGF serves as a negative regulator of BMP signaling.
We noted prominent HB-EGF staining in blood vessel walls in the
vascular region of the meniscus consistent with its known
expression by endothelial cells which can be promoted by VEGF30.
A recent study also found HB-EGF to be expressed at higher levels in
inﬂamed areas of synovium compared to normal/reactive areas
from patients undergoing knee replacement for OA31.
Further studies will be needed to measure the amounts of HB-
EGF present in normal and OA cartilage and to clarify the role of
HB-EGF in joint tissues in vivo. Becausemicewith a general deletion
of HB-EGF die at a very young age, tissue speciﬁc deletion will be
necessary to examine the role of HB-EGF in mice. Based on the
present ﬁndings and on studies to date with other EGFR ligands, as
well as with overactivation of EGFR signaling in mice with theMig-
6 deletion, we expect that excessive production of HB-EGF in joint
tissues will contribute to OA through altering the balance of
chondrocyte anabolic and catabolic activity.
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